ОБ ЭТОМ ЭПИЗОДЕ
Dr Xose Puente speaks with ecancertv at AACR2016 about his discoveries of mutations in non-coding regions driving tumourigensis in chronic lymphocytic leukaemia.
Using a library of genomic data from CLL patients, Dr Puente's lab were able to determine point mutations outside of the coding regions of patients DNA that gave rise to altered gene expression.
A single substitution in the 3' tail of Notch1, a cell cycle regulator, is reported as introducing a novel splicing site resulting in the deletion of 500 base pairs, including those which determine Notch1 persistence in healthy cells.
Another mutation in an intragenic region results in down-regulation of Pax5, essential for B cell maturation.
These results are among the first to indicate the clinical significance of non-coding DNA to cancer development.
Using a library of genomic data from CLL patients, Dr Puente's lab were able to determine point mutations outside of the coding regions of patients DNA that gave rise to altered gene expression.
A single substitution in the 3' tail of Notch1, a cell cycle regulator, is reported as introducing a novel splicing site resulting in the deletion of 500 base pairs, including those which determine Notch1 persistence in healthy cells.
Another mutation in an intragenic region results in down-regulation of Pax5, essential for B cell maturation.
These results are among the first to indicate the clinical significance of non-coding DNA to cancer development.
английский
США
РАСШИФРОВКА 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
ДРУГИЕ ЭПИЗОДЫ В ЭТОМ ПОДКАсте
Dr Rafaella Sordella speaks with ecancertv at AACR 2016 about cell plasticity affecting its susceptibility to therapies.
With specific regard to non-genetic mechanisms of resistance in cancer cells, Dr Sordella explains the flexible cell state, how some cells persist and respond to therapies, and …
Dr Philip Low speaks with ecancertv at AACR 2016 about a novel technique to selectively identify tumour cells in vivo.
With potentially toxic side effects to uncontrolled tumour lysis and hard-to-target heterogeneity, Dr Low describes a new method of using fluorescein dye to bridge tumours and T C…
Dr Martine Piccart presents at AACR 2016 about the results of the MINDACT trial.
Using a new diagnostic assay, Mammaprint, to scan for a 70 gene signature, Dr Piccart reports significant predictive potential for determining breast cancer relapse risk.
Dr Robert Gillies talks to ecancertv at AACR 2016 about novel imaging techniques in tumour habitats.
Considering the stalling durable response rate of many targeted-therapy patients due to tumour evolution, Dr Gillies discusses the value of multiple imaging techniques to determining tumour habitat…
Отказ от ответственности: Подкаст и иллюстрации, встроенные в эту страницу, взяты из ecancer.org, который является собственностью его владельца и не связан или не одобрен Listen Notes, Inc.
ИЗМЕНИТЬ
Спасибо, что помогаете поддерживать базу подкастов актуальной.
